PFE - Pfizer Inc.

NYSE - NYSE Delayed Price. Currency in USD
35.37
-0.19 (-0.53%)
At close: 4:00PM EST

35.24 -0.12 (-0.35%)
After hours: 4:13PM EST

Stock chart is not supported by your current browser
Previous Close35.56
Open35.37
Bid35.36 x 9900
Ask35.37 x 104600
Day's Range35.17 - 35.49
52 Week Range30.51 - 36.78
Volume13,937,231
Avg. Volume16,367,836
Market Cap210.83B
Beta1.07
PE Ratio (TTM)25.87
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield1.28 (3.62%)
Ex-Dividend Date2017-11-09
1y Target EstN/A
Trade prices are not sourced from all markets
  • Obamacare enrollment soars in first 11 days
    Yahoo Finance Videoyesterday

    Obamacare enrollment soars in first 11 days

    Open enrollment is going strong for the Affordable Care Act. Almost 1.5M people have signed up for Obamacare during the first two weeks of open enrollment. That's up a whopping 46% compared to the same time last year. Yahoo Finance’s Alexis Christoforous and Myles Udland figure out what’s behind the sharp increase.

  • GOP tax plan takes aim at Obamacare
    Yahoo Finance Video2 days ago

    GOP tax plan takes aim at Obamacare

    Senate Republicans have wanted to kill the Obamacare individual mandate for a long time and now they're looking to do it as part of their tax reform proposal. Senate Majority Leader Mitch McConnell says the GOP tax plan will now include a provision to repeal the Obamacare mandate, which requires everyone to have health insurance. Yahoo Finance’s Alexis Christoforous and Rick Newman breakdown what this means for Americans.

  • Associated Press2 hours ago

    Pfizer tells Nebraska not to use its drugs in execution

    LINCOLN, Neb. (AP) — Pharmaceutical company Pfizer is demanding that Nebraska return any drugs manufactured by the company or an affiliate that the state plans to use in an execution.

  • Market Realist6 hours ago

    Novartis on the Street: Analysts’ Recommendations in November

    Of the three analysts tracking Novartis in November 2017, one recommends a “strong buy,” while two recommend a “hold."

  • InvestorPlace6 hours ago

    Why It’s Time to Put Pfizer Inc. Stock on Your Watchlist

    Ever since its cholesterol-fighting drug Lipitor lost the crux of its patent protection back in 2011, Pfizer Inc. (NYSE:PFE) investors have approached PFE stock with caution. Early this week, Purkiss made a point of saying sales of Ibrance is being underestimated, suggesting that rather than achieving just a little less than $7 billion in revenue in 2023, it could actually produce nearly $13-billion worth of business that year as its approved uses were expanded and caregivers saw its efficacy.

  • Cancer Space Update: Label Expansion for Three Major Drugs
    Zacks6 hours ago

    Cancer Space Update: Label Expansion for Three Major Drugs

    This week three major drugs received approval for label expansion in new indications. Moreover, a small biotech launched its first drug as a treatment for kidney cancer.

  • These 3 Stocks Might as Well Not Even Be in the Dow Jones Industrials
    Motley Fool10 hours ago

    These 3 Stocks Might as Well Not Even Be in the Dow Jones Industrials

    Find out why these huge companies have almost no influence on the average.

  • Market Realistyesterday

    AstraZeneca’s Valuation after 3Q17 Earnings

    In 3Q17, AstraZeneca reported EPS of $0.56 on revenues of $6.2 billion compared to estimates of $0.71 for EPS on revenues of $6 billion.

  • Market Realistyesterday

    Which Products Are Driving Revenues for Antares Pharma in 2017?

    Sumatriptan is the only injectable triptan approved for use in the US. The product achieved a market share of 26.0% in 2Q17, up from 21.0% in 1Q17.

  • Reuters2 days ago

    Pfizer, Novartis agree UK price cuts for new breast cancer drugs

    Pfizer and Novartis have agreed price cuts for their rival breast cancer drugs Ibrance and Kisqali to ensure they can be used routinely within Britain's state-funded health service. Both are oral drugs, given in concert with hormonal therapies, that inhibit two proteins called CDK 4 and 6. A third CDK 4/6 drug from Eli Lilly is also licensed in the United States but not yet in Europe.

  • Despite Valeant Improvement, VRX Stock Price Is Still Too High
    InvestorPlace2 days ago

    Despite Valeant Improvement, VRX Stock Price Is Still Too High

    New CEO Joe Papa has done a nice job in his efforts to turn around Valeant Pharmaceuticals Intl Inc (NYSE:VRX). Generic drugmakers have been taken to the woodshed, with Teva Pharmaceutical Industries Ltd (NYSE:TEVA) down 67% year-to-date and Mallinckrodt PLC (NYSE:MNK) off 56%.

  • Why Pfizer Inc (PFE) Could Be A Buy
    Simply Wall St.2 days ago

    Why Pfizer Inc (PFE) Could Be A Buy

    Let’s talk about the popular Pfizer Inc (NYSE:PFE). The company’s shares received a lot of attention from a substantial price movement on the NYSE in the over the last fewRead More...